LifeScience Antibody Drug Conjugates
Pierre Fabre and RedRidge Bio Partner to Develop Biparatopic Antibody Drug Candidates
Pierre Fabre Laboratories and RedRidge Bio announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic...
March 13, 2025 | News
Navigating Biologics Development: Strategies for Regulatory Success, CMC Challenges, and Tech Transfer
Click here to Register Now! As the biologics field rapidly evolves, mastering regulatory pathways, process development, and tech transfer is essential for...
March 12, 2025 | News
WuXi XDC and AbTis Partner to Advance Site-Selective ADC Conjugation
WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza...
March 12, 2025 | News
Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...
March 11, 2025 | News
Nona Biosciences Unveils AI-Powered Hu-mAtrIx™ Platform to Transform Antibody Discovery
Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced to unveil its innovative AI-...
March 10, 2025 | News
CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...
March 06, 2025 | News
Frazier Life Sciences Launches Callio Therapeutics with $187M Series A to Advance Multi-Payload ADCs
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from&nb...
March 05, 2025 | News
WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production
EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...
March 04, 2025 | News
Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...
February 28, 2025 | News
Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...
February 28, 2025 | News
WuXi XDC Expands Partnership with LigaChem to Accelerate Next-Gen ADC Development
WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiz...
February 26, 2025 | News
Akeso, Summit Therapeutics, and Pfizer Join Forces to Advance Ivonescimab-ADC Combinations in Solid Tumor Trials
Akeso, Inc. announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collaboration with Pfizer Inc...
February 25, 2025 | News
Harbour BioMed and Insilico Medicine Partner to Accelerate AI-Driven Antibody Discovery
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...
February 21, 2025 | News
RemeGen Presents Promising Phase II Trial Results for Disitamab Vedotin and Toripalimab in Muscle-Invasive Bladder Cancer at ASCO GU 2025
RemeGen Co., Ltd. (RemeGen) has announced new efficacy and safety data from the Phase II clinical trial (NCT05297552, Study ID: RC48-C017) evaluating Disit...
February 17, 2025 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
